A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.
The medicine is now approved for eight indications across five different types of cancer in China.
The company’s RenovoCath Delivery System designed for targeted treatment of solid tumours
It adds Rezurock (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD)
Ind-Ra expects IPM revenue to grow over 12% YoY in FY22
Amptron’s R &D is based out of the US and this will enable Max to obtain US and other global certifications. Max will retain the right to market, sell and distribute the products in India.
Marketed under the brand name DGJAJ, it helps in the faster recovery of hospitalised patients and reduces supplemental oxygen dependence
At present 18 per cent of the local pharmaceutical market is under government's price control
In March 2016, Dr. Reddy’s had acquired the exclusive global rights (excluding Japan and Asia) to the investigational anti-cancer agent E7777 from Eisai Co.
Subscribe To Our Newsletter & Stay Updated
